| Each film-coated tablet contains 5 or 10 mg montelukast, №28
ATC Code: R05CB06, expectorants, excl. combinations with cough suppressants, mucolytics
Preclinically, ambroxol has been shown to increase respiratory tract secretion. It enhances pulmonary surfactant production and stimulates ciliary activity. These actions result in improved mucus flow and transport (mucociliary clearance). Improvement of mucociliary clearance has been shown in clinical pharmacological studies. Enhancement of fluid secretion and mucociliary clearance facilitates expectoration and eases cough.
Secretolytic therapy in acute and chronic bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport.
Ambroxol is indicated for the liquefaction of the mucus secretions of the respiratory tracts, in case of acute and chronic bronchoalveolar disorders (bronchitis, emphysema, tracheobronchitis, and chronic asthmatic bronchitis).
It is also indicated for the prevention of respiratory complications after retention of secretions following major surgical operations on the thorax – upper abdomen and after prolonged bed rest.
It must be administered concomitantly with the proper antibiotic during acute bronchitis exacerbations.